Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary11/03/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/03/16 -- Medgenics, Inc. (NASDAQ: MDGN) Presented Data Confirming Prevalence of Genetic Mutations in Pediatric ADHD at the 63 rd Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting Began Trading on the NASDAQ Global Markets Medgenics,
Toggle Summary10/29/2016
PHILADELPHIA , Oct. 29, 2016 /PRNewswire/ -- Medgenics, Inc. (NASDAQ: MDGN) – New data presented at AACAP's 63 rd Annual Meeting ( Oct. 24-29, 2016 in New York, NY ) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).  The
Toggle Summary10/26/2016
PHILADELPHIA, PA -- (Marketwired) -- 10/26/16 -- Medgenics, Inc. (NASDAQ: MDGN) will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results for the third quarter ended September 30, 2016 and discuss recent business updates.
Toggle Summary10/10/2016
PHILADELPHIA, PA -- (Marketwired) -- 10/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) (the "Company") announced today that it has been approved for listing on the NASDAQ Global Market , continuing to trade under the symbol "MDGN." Trading on the NASDAQ Global Market is expected to commence on October
Toggle Summary09/06/2016
PHILADELPHIA, PA -- (Marketwired) -- 09/06/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Monday, September 12, 2016 at 9:10
Toggle Summary08/04/2016
PHILADELPHIA, PA -- (Marketwired) -- 08/04/16 -- Medgenics, Inc. (NYSE MKT: MDGN) Initiated Phase 2/3 study of lead program in mGluR+ ADHD Entered into collaboration for second pediatric product in Inflammatory Bowel Disease Strengthened balance sheet with successful financing Medgenics, Inc.
Toggle Summary07/27/2016
PHILADELPHIA, PA -- (Marketwired) -- 07/27/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Thursday, August 4, 2016 at 8:30 a.m. EDT to report financial results for the second quarter ended June 30, 2016 and discuss recent business updates.
Toggle Summary06/21/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/21/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has
Toggle Summary06/20/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/20/16 -- Medgenics, Inc. (NYSE: MDGN), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement.
Toggle Summary06/17/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/17/16 -- Medgenics, Inc. (NYSE: MDGN) today announced the enrollment of the first patient into the SAGA ( S tudy of A dolescent G lutamate Receptor Network Copy Number Variant A DHD) trial -- a Phase 2/3 clinical trial to evaluate adolescent patients with